Wang et al., 2016 - Google Patents
Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailabilityWang et al., 2016
- Document ID
- 9607693085509884682
- Author
- Wang J
- Wang X
- Yang Y
- Chen X
- Mei X
- Publication year
- Publication venue
- CrystEngComm
External Links
Snippet
17β-estradiol (E2) is a steroid hormone with low oral bioavailability due to its low aqueous solubility (0.2–5 μg mL− 1). To improve its solubility and thus bioavailability, two co-crystals of E2 with isonicotinamide (INA)(1) and piperazine (PIP)(2) were successfully designed and …
- 230000036912 Bioavailability 0 title abstract description 13
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailability | |
US20120309968A1 (en) | Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof | |
Zhou et al. | Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals | |
AU2011307608B2 (en) | Crystalline naloxol-PEG conjugate | |
Lin et al. | Preparation, characterization, and evaluation of dipfluzine–benzoic acid co-crystals with improved physicochemical properties | |
Tanaka et al. | Application of spray freeze drying to theophylline-oxalic acid cocrystal engineering for inhaled dry powder technology | |
US20150344435A1 (en) | Process for preparating ivabradine hydrochloride form iv and methods of treatment of disease using ivabradine hydrochloride form iv | |
AU2014351028B2 (en) | Solid forms of Ivacaftor and processes for the preparation thereof | |
Zhu et al. | Stable cocrystals and salts of the antineoplastic drug apatinib with improved solubility in aqueous solution | |
AU2018303293B2 (en) | Amorphous form of vilanterol trifenatate and processes for the preparation thereof | |
CN103360331B (en) | Novel lamotrigine pharmaceutical co-crystal and preparation method thereof | |
WO2018010622A1 (en) | Crystalline form of chemical compound, and preparation method, composition, and application thereof | |
Cai et al. | Process control and in vitro/in vivo evaluation of aripiprazole sustained-release microcrystals for intramuscular injection | |
CN103936808A (en) | Isonicotinamide eutectic crystal of 17beta estradiol, and preparation method and application thereof | |
CN112778290B (en) | A kind of addition salt of S1P1 receptor agonist and its crystal form and pharmaceutical composition | |
Chen et al. | Pharmaceutical cocrystals of nomegestrol acetate with superior dissolution | |
EP2897955B1 (en) | New tiotropium bromide crystalline form | |
EP2681212A1 (en) | Crystalline compound comprising tiotropium bromide | |
CN110078679A (en) | A kind of lamotrigine pharmaceutical co-crystal and its preparation method and application | |
MX2009007785A (en) | Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin. | |
US20180291049A1 (en) | Crystalline Forms of Fosnetupitant | |
JP6594325B2 (en) | Crystal forms of tiotropium bromide and lactose | |
Zhang et al. | Dosable solvates of ivacaftor with high boiling point liquids | |
JP2018531249A6 (en) | Crystalline form of Phosnetupitant | |
WO2023187086A1 (en) | Amorphous solid form of amcenestrant |